CAL
BDTX icon

Capital Advisors Ltd’s Black Diamond Therapeutics BDTX Stock Holding History

Capital Advisors Ltd’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-476
Closed -$1K – 1224
2022
Q3 		$1K Buy
476
+301
+172% +$928 ﹤0.01% 960
2022
Q2 		$0 Buy
+175
New +$407 ﹤0.01% 1005
2022
Q1 		– Sell
-41
Closed – – 910
2021
Q4 		$0 Buy
+41
New +$286 ﹤0.01% 813

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Capital Advisors Ltd's BDTX Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Black Diamond Therapeutics (BDTX) in Q4 2022, closing a stake of 476 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in BDTX in Q4 2021 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 59 funds tracked by Wall St. Rank hold BDTX as of Q4 2022.

  • Capital Advisors Ltd reported no remaining Black Diamond Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 476 Black Diamond Therapeutics shares in Q4 2022, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 3 quarters.
  • Capital Advisors Ltd's Black Diamond Therapeutics position peaked at $1K in Q3 2022.
  • 59 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.